Pesonen Ullamari, Koch Werner, Schömig Albert, Kastrati Adnan
Department of Pharmacology and Clinical Pharmacology, University of Turku, PharmaCity, Turku, Finland.
J Endovasc Ther. 2003 Jun;10(3):566-72. doi: 10.1177/152660280301000323.
To identify if an association exists between the leucine 7 (Leu7) to proline 7 (Pro7) polymorphism located in the signal peptide of the preproneuropeptide Y (preproNPY) gene and restenosis after coronary stenting. The Pro7 allele of the preproNPY gene affects the plasma levels of human neuropeptide Y, a potent mitogen of vascular smooth muscle cells.
A population of 1850 consecutive patients with symptomatic coronary artery disease undergoing coronary stent implantation was enrolled in a study that featured angiography at 6 months and genotype determination. The primary endpoint was angiographically documented restenosis (> or =50% diameter stenosis) at 6 months. The secondary endpoint was the clinical outcome at 1 year (death, myocardial infarction, target vessel revascularization). Genotyping was based on the polymerase chain reaction with fluorescent allele-specific oligonucleotide probes (TaqMan method).
The carrier frequency of the rare Pro7 allele was 6.2%. Baseline, lesion-related, angiographic, and procedural parameters were similar in the patients with the Leu7/Leu7 genotype and carriers of the Pro7 allele (i.e., subjects with genotype Leu7/Pro7 or Pro7/Pro7). Restenosis rates at 6 months did not differ significantly between the groups (33% versus 30%, p=0.54). In addition, no relationship of the polymorphism with the clinical outcomes at 1 year was observed.
Our results suggest that the Leu7 to Pro7 polymorphism of the preproNPY gene is not associated with angiographic restenosis or adverse clinical events after stent placement in coronary arteries.
确定前神经肽Y（preproNPY）基因信号肽中亮氨酸7（Leu7）至脯氨酸7（Pro7）多态性与冠状动脉支架置入术后再狭窄之间是否存在关联。preproNPY基因的Pro7等位基因会影响人神经肽Y的血浆水平，人神经肽Y是血管平滑肌细胞的一种强效促有丝分裂原。
1850例连续的有症状冠状动脉疾病患者接受冠状动脉支架置入术，并纳入一项研究，该研究包括6个月时的血管造影和基因型测定。主要终点是6个月时血管造影记录的再狭窄（直径狭窄≥50%）。次要终点是1年时的临床结局（死亡、心肌梗死、靶血管血运重建）。基因分型基于聚合酶链反应和荧光等位基因特异性寡核苷酸探针（TaqMan法）。
罕见的Pro7等位基因的携带频率为6.2%。Leu7/Leu7基因型患者和Pro7等位基因携带者（即Leu7/Pro7或Pro7/Pro7基因型受试者）的基线、病变相关、血管造影和手术参数相似。两组6个月时的再狭窄率无显著差异（33%对30%，p = 0.54）。此外，未观察到该多态性与1年时临床结局之间的关系。
我们的结果表明，preproNPY基因的Leu7至Pro7多态性与冠状动脉支架置入术后的血管造影再狭窄或不良临床事件无关。
